Efficacy and safety of salvianolate and enoxaparin in the prevention of perioperative deep venous thrombosis in gastrointestinal surgery.

GASTROINTESTINAL surgery; DRUG efficacy; ENOXAPARIN; PERIOPERATIVE care; PROTHROMBIN time; PARTIAL thromboplastin time; HERBAL medicine; COMBINATION drug therapy; HEMATOCRIT; ANTICOAGULANTS; SURGERY; PATIENTS; DISEASE incidence; VENOUS thrombosis; COMPARATIVE studies; TREATMENT effectiveness; LOW-molecular-weight heparin; FIBRINOGEN; THROMBIN time; PLATELET count; DESCRIPTIVE statistics; RESEARCH funding; INTERNATIONAL normalized ratio; PATIENT safety; CHINESE medicine; FIBRIN fibrinogen degradation products; PHARMACODYNAMICS

Objective: In this study, the efficacy and safety of salvianolate were compared with enoxaparin in the prevention of perioperative deep vein thrombosis in gastrointestinal surgery. Methods: From October 2017 to September 2019, 563 patients who underwent gastrointestinal surgery were collected. Based on the inclusion and exclusion criteria, 119 patients were divided into two groups: enoxaparin group (n = 65) and salvianolate group (n = 54). Comparisons were made regarding the outcomes: prothrombin time (PT), prothrombin activity (PTA), international normalized ratio (INR), activated partial thromboplastin time (APTT), fibrinogen (FIB), thrombin time (TT), D‐dimer level (D‐D), platelet count (PLT), hematokrit (HCT), and incidence of deep vein thrombosis (DVT). Results: The main outcomes showed no significance between enoxaparin group and salvianolate group (p >.05). The incidence of DVT in salvianolate group was 1.85%, significantly lower than that in enoxaparin group (12.3%) (p <.05). No serious adverse reactions occurred in the two groups during treatment. Conclusion: Compared with enoxaparin, salvianolate has an advantage in the prevention of perioperative thrombosis in gastrointestinal surgery with a lower incidence of DVT. [ABSTRACT FROM AUTHOR]